GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (OTCPK:ONCSQ) » Definitions » Cyclically Adjusted Price-to-FCF

OncoSec Medical (OncoSec Medical) Cyclically Adjusted Price-to-FCF : (As of May. 16, 2024)


View and export this data going back to 1986. Start your Free Trial

What is OncoSec Medical Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


OncoSec Medical Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for OncoSec Medical's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Cyclically Adjusted Price-to-FCF Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoSec Medical's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, OncoSec Medical's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Cyclically Adjusted Price-to-FCF falls into.



OncoSec Medical Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

OncoSec Medical's Cyclically Adjusted FCF per Share for the quarter that ended in Jan. 2023 is calculated as:

For example, OncoSec Medical's adjusted Free Cash Flow per Share data for the three months ended in Jan. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jan. 2023 (Change)*Current CPI (Jan. 2023)
=-2.555/126.2230*126.2230
=-2.555

Current CPI (Jan. 2023) = 126.2230.

OncoSec Medical Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201304 -60.704 98.107 -78.101
201307 -48.185 98.557 -61.711
201310 -62.606 98.536 -80.198
201401 -45.475 98.692 -58.161
201404 -53.979 100.023 -68.118
201407 -57.925 100.520 -72.736
201410 -68.982 100.176 -86.919
201501 -72.625 98.604 -92.968
201504 -93.929 99.824 -118.770
201507 -93.524 100.691 -117.239
201510 -76.701 100.346 -96.480
201601 -64.961 99.957 -82.031
201604 -62.688 100.947 -78.385
201607 -53.759 101.524 -66.838
201610 -51.570 101.988 -63.824
201701 -42.367 102.456 -52.195
201704 -47.606 103.167 -58.245
201707 -47.711 103.278 -58.311
201710 -50.297 104.070 -61.004
201801 -38.829 104.578 -46.866
201804 -25.048 105.708 -29.909
201807 -25.817 106.324 -30.649
201810 -27.004 106.695 -31.946
201901 -22.628 106.200 -26.894
201904 -25.360 107.818 -29.689
201907 -18.227 108.250 -21.253
201910 -16.800 108.577 -19.530
202001 -15.279 108.841 -17.719
202004 -8.227 108.173 -9.600
202007 -8.959 109.318 -10.344
202010 -8.002 109.861 -9.194
202101 -8.328 110.364 -9.525
202104 -7.542 112.673 -8.449
202107 -4.736 115.183 -5.190
202110 -5.547 116.696 -6.000
202201 -5.603 118.619 -5.962
202204 -2.985 121.978 -3.089
202207 -3.864 125.002 -3.902
202210 -3.425 125.734 -3.438
202301 -2.555 126.223 -2.555

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


OncoSec Medical  (OTCPK:ONCSQ) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


OncoSec Medical Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical (OncoSec Medical) Business Description

Industry
Traded in Other Exchanges
N/A
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.
Executives
Robert J Delaversano officer: Principal Accounting Officer 217 W. MAIN STREET, SOMERVILLE NJ 08876
Spahr Stephany Foster director C/O ONCOSEC MEDICAL, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Robert H. Arch officer: President and CEO C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
George Chi officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Lin Shi director 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Margaret Dalesandro director ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534
Yuhang Zhao director 6 HORTON DR., CHESTER NJ 07930
Brian A Leuthner officer: Chief Operating Officer 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922
Daniel J. O'connor director C/O SEELOS THERAPEUTICS, INC., 300 PARK AVENUE, 12TH FLOOR, NEW YORK NY 10022
China Grand Pharmaceutical & Healthcare Holdings Ltd 10 percent owner, other: See Remarks UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Alpha Holdings, Inc. director, 10 percent owner GANGNAM-GU APGUJEONG-RO 62-GIL 17-10, SEOUL M5 06016
Kellie Malloy Foerter officer: Chief Operating Officer C/O ONCOSEC MEDICAL INCORPORATED, 24 N. MAIN STREET, PENNINGTON NJ 08534-2218
Herbert Kim Lyerly director C/O ONCOSEC MEDICAL INCORPORATED, 24 NORTH MAIN STREET, PENNINGTON NJ 08534-2218
Chao Zhou director UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000
Grand Decade Developments Ltd 10 percent owner, other: See Remarks UNIT 3302, 33/F, THE CENTER, 99 QUEEN'S ROAD, CENTRAL K3 000000

OncoSec Medical (OncoSec Medical) Headlines